Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16818714 | 0.90 | BRD4 (0.81) | BRD4 | |
| SCHEMBL16818462 | 0.88 | BRD4 (0.82) | BRD4 | |
| SCHEMBL16818847 | 0.86 | BRD4 (0.79) | BRD4 | |
| SCHEMBL16818554 | 0.86 | BRD4 (0.79) | BRD4 | |
| SCHEMBL16818489 | 0.84 | BRD4 (0.76) | BRD4 | |
| SCHEMBL16818785 | 0.84 | BRD4 (0.85) | BRD4 | |
| SCHEMBL16818677 | 0.83 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16818640 | 0.83 | BRD4 (0.74) | BRD4 | |
| SCHEMBL16839985 | 0.82 | BRD4 (0.88) | BRD4 | |
| SCHEMBL16818769 | 0.82 | BRD4 (0.75) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-01-04 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2015095492-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 5/4885BRD9 7/4885 |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | BRD1, BRD3, BRD2 | BRD4 5/4885BRD9 7/4885 |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 5/4885BRD9 7/4885 |
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | BRD4 5/4885BRD9 7/4885 |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 5/4885BRD9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.